ArticleCurrent diabetes reviews2026
Comparative Clinical and Metabolic Outcomes of GLP-1 Receptor Agonists
Article in Current diabetes reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis research is designed to compare the clinical characteristics, metabolic outcomes, and safety profiles of patients with Type 1 Diabetes (T1D) treated with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) against Sodium-Glucose co-transporter 2 (SGLT2) inhibitors in a real-world clinical setting over 12 months.
methodsData from 112 adult T1D patients on intensive insulin therapy at Prince Sultan Military Medical City in Riyadh were examined for this retrospective cohort study. Among the 112 T1D, 96 were treated with GLP-1 receptor agonists and 16 were treated with SGLT2 inhibitors. Baseline demographics, the presence of comorbidities, diabetes complications, glycemic control (HbA1c), weight, insulin dosage, renal function, and lipid profiles were assessed at initiation and after 12 months of treatment.
resultsPatients getting GLP-1 receptor agonists were younger (p = 0.006), had shorter diabetes duration (p = 0.030), and were more likely to use insulin pumps (p = 0.040). The SGLT2 group showed significantly higher albumin-to-creatinine ratios (p = 0.047) and higher statin use (p = 0.038). GLP-1 therapy led to significant HbA1c (p < 0.05) and weight reduction, while SGLT2 treatment improved renal markers and reduced insulin dose. LDL cholesterol decreased significantly in the GLP-1 group (p = 0.014),while the SGLT2 group showed more favorable changes in HDL and total cholesterol. Comorbidities and diabetes related complications were similar between groups. DISCUSSION: GLP-1 RAs produced notable reductions in HbA1c levels and weight reduction, while SGLT2 inhibitors offered renal protection and decreased insulin needs. These real-world findings emphasize the value of tailoring adjunct therapies to each patient's profile. Personalized treatment strategies are crucial for optimizing metabolic outcomes in T1D.
conclusionBoth GLP-1 RAs and SGLT2 inhibitors effectively improve glycemic control and cardiovascular risk markers in T1D, with distinct advantages in weight loss and renal function, respectively. These findings highlight the value of personalized adjunct therapy choices to optimize patient outcomes. Larger prospective studies are needed to confirm long-term benefits and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.